findmyKOL
Clinical trialNCT02922777CompletedPhase 1Interventional

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

SponsorUniversity of Texas Southwestern Medical CenterEnrollment23Non-Small Cell Lung Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Texas Southwestern Medical Center

    Dallas, Texas, United States

  • Covenant Health Systems/joe Arrington Cancer Treatment and Research Center

    Lubbock, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2016
Primary completion
6 Feb 2023
Completion
4 Apr 2023
Last update posted
21 Feb 2024
Registered enrollment
23
Registry id
NCT02922777

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.